GNFT (GNFT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNFT (GNFT) trades at $8.95 with AI Score 69/100 (Buy). Genfit S. A. is a biopharmaceutical company focused on developing treatments for metabolic and liver diseases. Market cap: 446M, Sector: Healthcare.
Last analyzed: Mar 15, 2026GNFT (GNFT) Healthcare & Pipeline Overview
Genfit S.A. is a biopharmaceutical company specializing in the discovery and development of treatments for metabolic and liver-related diseases, including primary biliary cholangitis and NASH. Their pipeline features drug candidates like Elafibranor and diagnostic solutions such as NIS4 technology, positioning them within the competitive biotechnology sector.
Investment Thesis
Genfit S.A. presents a compelling investment case centered on its pipeline of drug candidates and diagnostic solutions targeting liver diseases. Elafibranor, in Phase 3 trials for PBC, represents a near-term value driver. The development of NIS4 technology for NASH diagnosis and GNS561 for CCA provide further growth potential. However, the company's negative profit margin of -85.9% and reliance on clinical trial outcomes pose significant risks. Successful commercialization of NASHnext and GNS561 through licensing agreements could improve revenue streams. Investors should closely monitor clinical trial results and regulatory approvals.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.45 billion reflects investor valuation of Genfit's pipeline and technology.
- Negative P/E ratio of -10.90 indicates the company is currently not profitable.
- Gross margin of 93.1% demonstrates strong potential profitability of the company's products, if commercialized successfully.
- Beta of 0.87 suggests the stock is slightly less volatile than the overall market.
- Elafibranor in Phase 3 clinical trials represents a significant potential value driver.
Competitors & Peers
Strengths
- Proprietary drug candidates in clinical development.
- Strong expertise in liver disease research.
- Strategic partnerships with leading healthcare companies.
- High gross margin potential.
Weaknesses
- Negative profit margin.
- Reliance on clinical trial outcomes.
- Limited commercialized products.
- High research and development costs.
Catalysts
- Results from Phase 3 clinical trial of Elafibranor for primary biliary cholangitis (PBC).
- Development and commercialization of NIS4 technology for NASH diagnosis.
- Progress of GNS561 in Phase 1b/2 trial for cholangiocarcinoma (CCA).
- Advancement of Nitazoxanide in Phase 1 trial for acute-on-chronic liver failure.
Risks
- Clinical trial failures for drug candidates.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other biotechnology companies.
- Patent expiration and loss of exclusivity.
- Negative profit margin and reliance on external funding.
Growth Opportunities
- Elafibranor for Primary Biliary Cholangitis (PBC): Elafibranor, currently in Phase 3 clinical trials, represents a significant growth opportunity if approved for PBC treatment. The PBC market is estimated to reach billions of dollars, and a successful launch could generate substantial revenue for Genfit. The timeline for potential approval is dependent on clinical trial results and regulatory review, but a launch within the next 2-3 years is possible.
- NIS4 Technology for NASH Diagnosis: The development and commercialization of NIS4 technology for NASH diagnosis offers a substantial growth opportunity. The market for NASH diagnostics is expanding rapidly due to the increasing prevalence of the disease. Genfit's partnership with Labcorp for NASHnext commercialization provides a competitive advantage. The timeline for widespread adoption depends on validation studies and market acceptance.
- GNS561 for Cholangiocarcinoma (CCA): GNS561, currently in Phase 1b/2 trials for CCA, presents a long-term growth opportunity. CCA is a rare but aggressive cancer with limited treatment options. Successful clinical trial results and regulatory approval could lead to significant revenue potential. The timeline for potential commercialization is several years, given the early stage of development.
- Nitazoxanide for Acute-on-Chronic Liver Failure: The development of Nitazoxanide for acute-on-chronic liver failure represents another potential growth driver. This condition has a high mortality rate and limited treatment options. Positive Phase 1 trial results could lead to further development and potential commercialization. The timeline for potential approval is uncertain, but it could provide a valuable addition to Genfit's pipeline.
- Strategic Partnerships and Licensing Agreements: Genfit's strategy of forming strategic partnerships and licensing agreements, such as those with Labcorp and Genoscience Pharma, provides a sustainable growth opportunity. These collaborations can accelerate the development and commercialization of its products and expand its market reach. Continued pursuit of such partnerships will be crucial for long-term success.
Opportunities
- Growing market for liver disease treatments.
- Expansion of diagnostic solutions for NASH.
- Potential for regulatory approval of Elafibranor.
- Further strategic partnerships and licensing agreements.
Threats
- Competition from other biotechnology companies.
- Clinical trial failures.
- Regulatory hurdles.
- Patent expiration.
Competitive Advantages
- Proprietary drug candidates and diagnostic technologies.
- Strong intellectual property protection through patents.
- Strategic partnerships with leading healthcare companies.
- Expertise in the field of metabolic and liver diseases.
About GNFT
Genfit S.A., established in 1999 and headquartered in Loos, France, is a biopharmaceutical company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver diseases. The company's lead product, Elafibranor, is currently in Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). Genfit is also developing NIS4 technology, a diagnostic tool for nonalcoholic steatohepatitis (NASH) and fibrosis, and GNS561, undergoing Phase 1b/2 trials for cholangiocarcinoma (CCA). Additionally, they are in Phase 1 trials with Nitazoxanide for acute-on-chronic liver failure. Genfit has strategic licensing agreements with Labcorp for the commercialization of NASHnext, a blood-based diagnostic test, and with Genoscience Pharma for the development of GNS561 for CCA. With approximately 180 employees, Genfit is focused on addressing unmet medical needs in the field of liver diseases, striving to improve patient outcomes through innovative research and development.
What They Do
- Discovers and develops drug candidates for metabolic and liver-related diseases.
- Develops diagnostic solutions for liver diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its products from health authorities.
- Commercializes its products through partnerships and licensing agreements.
- Focuses on addressing unmet medical needs in the field of liver diseases.
- Develops NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis.
Business Model
- Develops and patents novel drug candidates and diagnostic solutions.
- Out-licenses or partners with other companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Focuses on research and development to expand its product pipeline.
Industry Context
Genfit operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for liver disease treatments, particularly NASH and PBC, is growing due to increasing prevalence and limited treatment options. Genfit's focus on innovative diagnostic solutions and strategic partnerships positions it to capitalize on this growth. Competitors are also developing therapies for these conditions, creating a dynamic and evolving landscape.
Key Customers
- Patients suffering from metabolic and liver-related diseases.
- Healthcare providers who prescribe and administer treatments.
- Diagnostic laboratories that utilize diagnostic solutions.
- Pharmaceutical companies that partner with Genfit for commercialization.
Financials
Chart & Info
GNFT (GNFT) stock price: $8.95 (+0.35, +4.07%)
Latest News
-
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
globenewswire.com · Feb 12, 2026
-
Earnings Scheduled For April 24, 2025
benzinga · Apr 24, 2025
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Jun 30, 2023
-
Earnings Scheduled For September 29, 2021
· Sep 29, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNFT.
Price Targets
Wall Street price target analysis for GNFT.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNFT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Earnings Scheduled For April 24, 2025
12 Health Care Stocks Moving In Friday's Intraday Session
Earnings Scheduled For September 29, 2021
Leadership: M. Pascal Prigent
Chief Executive Officer
M. Pascal Prigent serves as the Chief Executive Officer of Genfit S.A. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Genfit, he held leadership positions at various global healthcare companies, focusing on strategic development and commercial operations. He brings a wealth of knowledge in drug development, regulatory affairs, and market access. His expertise is crucial for guiding Genfit through its clinical development programs and commercialization efforts.
Track Record: Since assuming the role of CEO, M. Pascal Prigent has focused on advancing Genfit's pipeline of drug candidates and diagnostic solutions. Key achievements include progressing Elafibranor through Phase 3 clinical trials and securing strategic partnerships for commercialization. He has also overseen the development of NIS4 technology for NASH diagnosis. His leadership is aimed at driving long-term growth and creating value for shareholders.
GNFT ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. GNFT, as an ADR, allows U.S. investors to invest in Genfit S.A. without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars, simplifying trading and reporting for U.S. investors. The underlying shares are held by a custodian bank in the company's home country.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About GNFT (GNFT) — Healthcare
What does Genfit S.A. do?
Genfit S.A. is a biopharmaceutical company that focuses on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases. Their primary focus is on conditions like primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). The company's pipeline includes Elafibranor, a drug in Phase 3 clinical trials for PBC, and NIS4 technology, a diagnostic tool for NASH. Genfit aims to address unmet medical needs in the field of liver diseases through innovative research and strategic partnerships.
What do analysts say about GNFT stock?
Analyst coverage of GNFT stock reflects a focus on the company's pipeline and potential for growth in the liver disease treatment market. Key valuation metrics include the potential revenue from Elafibranor if approved for PBC and the market opportunity for NASH diagnostics. Growth considerations center on clinical trial results, regulatory approvals, and commercialization efforts. Analyst consensus is cautiously optimistic, recognizing the inherent risks and uncertainties associated with biotechnology companies.
What are the main risks for GNFT?
The main risks for GNFT include the potential for clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. Clinical trial failures could significantly impact the company's pipeline and valuation. Regulatory delays or rejections could also hinder the commercialization of its products. Competition from larger pharmaceutical companies with greater resources poses a constant threat. Additionally, patent expiration and the need for continued funding are ongoing risks.
How does Genfit S.A. manage patent expiration risks?
Genfit S.A. manages patent expiration risks through a multi-faceted approach, including actively seeking patent protection for its novel drug candidates and diagnostic technologies. The company strategically builds a portfolio of patents with staggered expiration dates to ensure continued market exclusivity. Furthermore, Genfit invests in research and development to create new and improved products, extending its competitive advantage beyond the initial patent life. They also explore lifecycle management strategies to maximize the value of their existing products.
What revenue streams does Genfit S.A. have in healthcare?
Genfit S.A.'s revenue streams in healthcare primarily consist of licensing fees, milestone payments, and royalties generated through strategic partnerships and collaborations. The company's licensing agreement with Labcorp for the commercialization of NASHnext represents a significant revenue opportunity. Additionally, Genfit anticipates future revenue from the potential commercialization of Elafibranor for PBC and GNS561 for CCA. These revenue streams are dependent on successful clinical trial outcomes, regulatory approvals, and market adoption.
What are the key factors to evaluate for GNFT?
GNFT (GNFT) currently holds an AI score of 69/100, indicating moderate score. Key strength: Proprietary drug candidates in clinical development. Primary risk to monitor: Clinical trial failures for drug candidates. This is not financial advice.
How frequently does GNFT data refresh on this page?
GNFT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNFT's recent stock price performance?
Recent price movement in GNFT (GNFT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary drug candidates in clinical development. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market conditions and competitive landscape may evolve.